Autism

Neuropharm remains committed to serving the needs of patients with autism and is currently analyzing the SOFIA study data. We expect to be able to define alternatives for further development of NPL-2008 in the coming months with the aim of seeking marketing authorization from the US FDA. A projected timeline will be available once plans have been finalized.